{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NMS", "regularMarketChangePercent": 0.8880294, "regularMarketPrice": 750.96, "firstTradeDateMilliseconds": 670602600000, "priceHint": 2, "earningsTimestamp": 1683203400, "earningsTimestampStart": 1690893000, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingPE": 20.546103, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 36.55, "epsForward": 43.27, "epsCurrentYear": 41.47, "priceEpsCurrentYear": 18.108513, "sharesOutstanding": 107892000, "bookValue": 219.376, "fiftyDayAverage": 788.021, "fiftyDayAverageChange": -37.060974, "fiftyDayAverageChangePercent": -0.04703044, "twoHundredDayAverage": 730.12256, "twoHundredDayAverageChange": 20.837463, "twoHundredDayAverageChangePercent": 0.028539678, "marketCap": 82968313856, "forwardPE": 17.355211, "priceToBook": 3.423164, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.1 - Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "Regeneron Pharmaceuticals, Inc.", "longName": "Regeneron Pharmaceuticals, Inc.", "messageBoardId": "finmb_33715", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 6.6100464, "regularMarketTime": 1684180805, "regularMarketDayHigh": 751.97, "regularMarketDayRange": "743.05 - 751.97", "regularMarketDayLow": 743.05, "regularMarketVolume": 343245, "regularMarketPreviousClose": 744.35, "bid": 0.0, "ask": 0.0, "bidSize": 12, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 744.81, "averageDailyVolume3Month": 574166, "averageDailyVolume10Day": 611150, "fiftyTwoWeekLowChange": 212.95001, "fiftyTwoWeekLowChangePercent": 0.3958105, "fiftyTwoWeekRange": "538.01 - 837.55", "fiftyTwoWeekHighChange": -86.589966, "fiftyTwoWeekHighChangePercent": -0.10338483, "fiftyTwoWeekLow": 538.01, "fiftyTwoWeekHigh": 837.55, "displayName": "Regeneron Pharmaceuticals", "symbol": "REGN"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "777 Old Saw Mill River Road", "city": "Tarrytown", "state": "NY", "zip": "10591-6707", "country": "United States", "phone": "914 847 7000", "website": "https://www.regeneron.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.", "fullTimeEmployees": 12099, "companyOfficers": [{"maxAge": 1, "name": "Dr. Leonard S. Schleifer M.D., Ph.D.", "age": 69, "title": "Co-Founder, Pres, CEO & Director", "yearBorn": 1953, "fiscalYear": 2022, "totalPay": {"raw": 7004069, "fmt": "7M", "longFmt": "7,004,069"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 256815824, "fmt": "256.82M", "longFmt": "256,815,824"}}, {"maxAge": 1, "name": "Dr. George D. Yancopoulos M.D., Ph.D.", "age": 62, "title": "Co-Founder, Pres, Chief Scientific Officer & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 6593696, "fmt": "6.59M", "longFmt": "6,593,696"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 242710064, "fmt": "242.71M", "longFmt": "242,710,064"}}, {"maxAge": 1, "name": "Mr. Robert E. Landry Jr.", "age": 58, "title": "Exec. VP of Fin. & CFO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 1839460, "fmt": "1.84M", "longFmt": "1,839,460"}, "exercisedValue": {"raw": 11097488, "fmt": "11.1M", "longFmt": "11,097,488"}, "unexercisedValue": {"raw": 25114408, "fmt": "25.11M", "longFmt": "25,114,408"}}, {"maxAge": 1, "name": "Dr. Andrew J. Murphy Ph.D.", "age": 63, "title": "Exec. VP of Research", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 1622950, "fmt": "1.62M", "longFmt": "1,622,950"}, "exercisedValue": {"raw": 19388300, "fmt": "19.39M", "longFmt": "19,388,300"}, "unexercisedValue": {"raw": 83458888, "fmt": "83.46M", "longFmt": "83,458,888"}}, {"maxAge": 1, "name": "Mr. Daniel P. Van Plew", "age": 49, "title": "Exec. VP and GM of Industrial Operations & Product Supply", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 1954399, "fmt": "1.95M", "longFmt": "1,954,399"}, "exercisedValue": {"raw": 45282380, "fmt": "45.28M", "longFmt": "45,282,380"}, "unexercisedValue": {"raw": 24788798, "fmt": "24.79M", "longFmt": "24,788,798"}}, {"maxAge": 1, "name": "Ms. Marion E. McCourt", "age": 62, "title": "Exec. VP of Commercial", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 1500262, "fmt": "1.5M", "longFmt": "1,500,262"}, "exercisedValue": {"raw": 4246309, "fmt": "4.25M", "longFmt": "4,246,309"}, "unexercisedValue": {"raw": 8790830, "fmt": "8.79M", "longFmt": "8,790,830"}}, {"maxAge": 1, "name": "Ms. Patrice  Gilooly", "title": "Sr. VP of Quality Assurance & Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher R. Fenimore", "age": 51, "title": "Sr. VP, Head of Accounting & Controller", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gerald  Underwood", "title": "Sr. VP of Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bob  McCowan", "title": "Sr. VP of IT & Chief Information Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}